Black Diamond Therapeutics (BDTX) EBIT Margin (2025)
Black Diamond Therapeutics' EBIT Margin history spans 1 years, with the latest figure at 77.9% for Q1 2025.
- For Q1 2025, EBIT Margin changed N/A year-over-year to 77.9%; the TTM value through Dec 2025 reached 17.89%, changed N/A, while the annual FY2025 figure was 17.89%, N/A changed from the prior year.
- EBIT Margin reached 77.9% in Q1 2025 per BDTX's latest filing.
- In the past five years, EBIT Margin ranged from a high of 77.9% in Q1 2025 to a low of 77.9% in Q1 2025.